Napat Prompat

Mr. Napat Prompat

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2024 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
SKSoemwit Khongwichit
Soemwit Khongwichit
ANAekkaraj Nualla-ong
Aekkaraj Nualla-ong
NPNapat Prompat
Napat Prompat
MAMaliwan Amatatongchai
Maliwan Amatatongchai
PLPeter Lieberzeit
Peter Lieberzeit
SCSuticha Chunta
Suticha Chunta

25 July 2024 in Advanced Theory and Simulations
Verified
Journal Article
Closed access
PNPanik Nadee
Panik Nadee
NPNapat Prompat
Napat Prompat
MYMontarop Yamabhai
Montarop Yamabhai
SSSurasak Sangkhathat
Surasak Sangkhathat
SBSoottawat Benjakul
Soottawat Benjakul
JSJirakrit Saetang
Jirakrit Saetang

28 April 2025 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
JSJirakrit Saetang
Jirakrit Saetang
Montarop YamabhaiMontarop Yamabhai
Montarop Yamabhai
KRKuntalee Rangnoi
Kuntalee Rangnoi
NPNapat Prompat
Napat Prompat
THThaiyawat Haewphet
Thaiyawat Haewphet
SBSoottawat Benjakul
Soottawat Benjakul

Verified
Journal Article
Open access
PDF file
CPChariya Peeyatu
Chariya Peeyatu
NPNapat Prompat
Napat Prompat
SVSupayang Voravuthikunchai
Supayang Voravuthikunchai
NRNiran Roongsawang
Niran Roongsawang
SSSurasak Sangkhathat
Surasak Sangkhathat
VTVaromyalin Tipmanee
Varomyalin Tipmanee
Engineered interleukin-18 (IL-18) has attracted interest as a cytokine-based treatment. However, knowledge-based mutagenesis of IL-18 has been reported for only a few regions of the protein structures, including binding sites I and II. When coupled with the binding region mutant (E6K), the non-binding residue of IL-18, Thr63 (T63), has been shown to increase the flexibility of the binding loop. Nevertheless, the function of Thr63 in conformational regulation is still unknown. Using homology modeling, molecular dynamics simulation, and structural analysis, we investigated the effects of Thr63 alteration coupling with E6K on conformational change pattern, binding loop flexibility, and the hydrogen bond network. The results indicate that the 63rd residue was significantly associated with hydrogen-bond relaxation at the core β-barrel binding sites I and II Glu85-Ile100 loop. This result provided conformational and flexible effects to binding sites I and III by switching their binding loops and stabilizing the 63rd residue cavity. These findings may pave the way for the conceptualization of a new design for IL-18 proteins by modifying non-binding residues for structure-based drug development.


Verified
Journal Article
Open access
PDF file
WKWannakorn Khopanlert
Wannakorn Khopanlert
NPNapat Prompat
Napat Prompat
JSJirakrit Saetang
Jirakrit Saetang
KMKajornkiat Maneechai
Kajornkiat Maneechai
SOShingo Okuno
Shingo Okuno
JJJakrawadee Julamanee
Jakrawadee Julamanee
CD19-chimeric antigen receptor (CAR) has shown promising outcomes in B-cell malignancies. However, relapses due to poor CAR-T persistence and antigen escape have occurred. CD37 is a potential alternative immunotherapy for CD19− tumors. Inferior CAR-T cytotoxicity was observed in CD37CAR-T compared to CD19CAR-T model that was possibly due to lower CD37CAR affinity. To alleviate CD37CAR functions, we optimized the most prevalent linkers, Whitlow (18aaL) and glycine–serine (GS4L). CD37.GS4L CAR-T showed higher transduction efficiency and T-cell expansion contributed by minimizing T-cell fratricide. In chronic antigen stimulation, CD37.GS4L CAR demonstrated robust T-cell proliferation while preserving stemness and a decrease in induced exhaustion phenotype, which resulted in greater tumoricidal activity among various CD37+ malignancies. In silico analysis showed that CD37.GS4L scFv altered structural dynamic behaviors by facilitating variable heavy-chain region closer to CD37 receptor with higher binding affinity and less aggregation of negatively charged protein, which contributed to lower tonic signaling during CAR activation and diminished exhaustion. Ultimately, effective anti-tumor control with notable memory T-cell persistence was exhibited in Burkitt lymphoma mice treated with CD37.GS4L CAR-T. Additionally, CD37.GS4L CAR-T illustrated the potential in vivo cytotoxicity in myeloma-inoculated mice. In summary, the flexibility and affinity of glycine–serine linker of CD37CAR can potentiate CAR-T functionality.